L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
OBJECTIVE
To assess the impact of different surgical targets and techniques, such as ablation and deep brain stimulation, to treat patients with L-dopa-induced dyskinesia (LID), a major therapeutic complication of Parkinson's disease.


METHODS
This review analyzes the effects of early surgical procedures to treat hyperkinesia and the current methods and targets used to combat LID in Parkinson's disease, which are mainly thalamotomy, pallidotomy, and deep brain stimulation of the globus pallidus internus and the subthalamic nucleus.


RESULTS
Available information indicates that surgery of the globus pallidus internus and thalamus (the pallidal receiving area) and of the subthalamic nucleus has a pronounced antidyskinetic effect. This effect is associated with a concomitant improvement in the parkinsonian ("off"-medication) state. Although it is more profound with pallidal and subthalamic surgery, such an effect can also be observed to some extent with thalamic surgery. The latter is attributable to the fact that surgery of the ventralis intermedius is primarily effective for treating tremor. An integral pallidothalamic pathway is needed for dyskinesia to be expressed. Thus, LID is less frequent after subthalamotomy or deep brain stimulation of the subthalamic nucleus through a functional effect mediated by the physiological normalization of the motor system and by an indirect effect associated with a reduction in the daily dose of L-dopa.


CONCLUSIONS
Surgery is the only treatment available for Parkinson's disease that can predictably improve both the parkinsonian motor syndrome and LID. The exact mechanisms involved in these effects are not well understood. Pallidal and thalamic surgery affecting pallidal relays reduce LID frequency by disrupting the pallidothalamic circuit, probably eliminating the neuronal activity associated with dyskinesia. Alternatively, the antidyskinetic effect of subthalamic nucleus surgery may in part be attributable to a reduction in the L-dopa dose as well as to the stabilization of the basal ganglia circuits after the surgical procedure.
Guridi
Jorge
J
Division of Neurosurgery, Neuroscience Department, University Clinic, University of Navarra, Pamplona, Spain. jguridi@unav.es
Obeso
Jose A
JA
Rodriguez-Oroz
Maria C
MC
Lozano
Andres A
AA
Manrique
Miguel
M
D000978:Antiparkinson Agents / Q000009:adverse effects*; D046690:Deep Brain Stimulation; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D019635:Neurosurgical Procedures; D010300:Parkinson Disease / Q000188:drug therapy*; D013238:Stereotaxic Techniques
D000978:Antiparkinson Agents; D007980:Levodopa